Rapamycin, an mTOR inhibitor, was approved to treat metastatic renal cell carcinoma and breast cancer patients.[21] Everolimus, another mTOR inhibitor, was found to have only a moderate therapeutic effect on colon cancer in multiple clinical trials, but when used in combination with bevacizumab, it was found to prolong progression‐free survival in patients with metastatic colon cancer.[42] Here, we used rapamycin and everolimus to evaluate the MTA1‐ATP5A‐mediated AMPK/mTOR pathway in cancer treatment. This evidence concerns the gene ATP5F1A and breast cancer.